Found: 36
Select item for more details and to access through your institution.
Correction to: Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.
- Published in:
- 2024
- Publication type:
- Correction Notice
Closing the gap: proposing a socio-ecological framework to make cancer clinical trials more accessible, equitable, and acceptable to adolescents and young adults.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 918, doi. 10.1093/oncolo/oyae257
- By:
- Publication type:
- Article
Correction to: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
- Published in:
- 2024
- Publication type:
- Correction Notice
Highlights of ASCO 2024.
- Published in:
- 2024
- By:
- Publication type:
- Proceeding
Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1552, doi. 10.1093/oncolo/oyae244
- By:
- Publication type:
- Article
Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 999, doi. 10.1093/oncolo/oyae243
- By:
- Publication type:
- Article
Correction to: Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
- Published in:
- 2024
- Publication type:
- Correction Notice
Correction to: Prediction of moderate and severe toxicities of chemotherapy in older patients with cancer: a propensity weighted analysis of ELCAPA cohort.
- Published in:
- 2024
- Publication type:
- Correction Notice
Correction to: Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.
- Published in:
- 2024
- Publication type:
- Correction Notice
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 957, doi. 10.1093/oncolo/oyae210
- By:
- Publication type:
- Article
Correction to: Enhanced stiffness in peri-cancerous tissue: a marker of poor prognosis in papillary thyroid carcinoma with lymph node metastasis.
- Published in:
- 2024
- Publication type:
- Correction Notice
Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 997, doi. 10.1093/oncolo/oyae207
- By:
- Publication type:
- Article
Advances and future directions in ROS1 fusion-positive lung cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 943, doi. 10.1093/oncolo/oyae205
- By:
- Publication type:
- Article
Association of human papillomavirus genotype and phylogenic clade with oropharyngeal cancer outcomes.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 966, doi. 10.1093/oncolo/oyae202
- By:
- Publication type:
- Article
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1532, doi. 10.1093/oncolo/oyae201
- By:
- Publication type:
- Article
Correction to: Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
- Published in:
- 2024
- Publication type:
- Correction Notice
Social supports in patients with cancer attending an Irish cancer center: a cross-sectional study.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1621, doi. 10.1093/oncolo/oyae196
- By:
- Publication type:
- Article
Assessment of psycho-oncology in the Middle East and North Africa region: a systematic review and meta-analysis.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1452, doi. 10.1093/oncolo/oyae193
- By:
- Publication type:
- Article
Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1501, doi. 10.1093/oncolo/oyae190
- By:
- Publication type:
- Article
Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1615, doi. 10.1093/oncolo/oyae189
- By:
- Publication type:
- Article
Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 978, doi. 10.1093/oncolo/oyae187
- By:
- Publication type:
- Article
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1435, doi. 10.1093/oncolo/oyae177
- By:
- Publication type:
- Article
Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1593, doi. 10.1093/oncolo/oyae176
- By:
- Publication type:
- Article
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1480, doi. 10.1093/oncolo/oyae168
- By:
- Publication type:
- Article
Patient-reported convenience and effectiveness of telehealth for breast cancer management.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1470, doi. 10.1093/oncolo/oyae165
- By:
- Publication type:
- Article
Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1511, doi. 10.1093/oncolo/oyae160
- By:
- Publication type:
- Article
Current status of advance care planning, palliative care consultation, and end-of-life care in patients with glioblastoma in South Korea.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1586, doi. 10.1093/oncolo/oyae159
- By:
- Publication type:
- Article
Prediction of moderate and severe toxicities of chemotherapy in older patients with cancer: a propensity weighted analysis of ELCAPA cohort.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1523, doi. 10.1093/oncolo/oyae157
- By:
- Publication type:
- Article
Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1565, doi. 10.1093/oncolo/oyae154
- By:
- Publication type:
- Article
National survey of patient perspectives on cost discussions among recipients of copay assistance.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1540, doi. 10.1093/oncolo/oyae148
- By:
- Publication type:
- Article
Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1575, doi. 10.1093/oncolo/oyae147
- By:
- Publication type:
- Article
Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1425, doi. 10.1093/oncolo/oyae134
- By:
- Publication type:
- Article
Opioid metabolism and drug-drug interaction in cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 931, doi. 10.1093/oncolo/oyae094
- By:
- Publication type:
- Article
Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 922, doi. 10.1093/oncolo/oyae089
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 986, doi. 10.1093/oncolo/oyae142
- By:
- Publication type:
- Article
A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. e1492, doi. 10.1093/oncolo/oyae140
- By:
- Publication type:
- Article